UK-based health-tech company Evaro has raised $25 million in a Series A funding round as it looks to expand its embedded healthcare platform and respond to growing demand for accessible medical services.
The round was led by AlbionVC, with additional backing from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC and BBI. The funding reflects growing investor confidence in Evaro’s approach, which enables consumer brands to offer regulated medical services through their existing digital platforms.
Evaro provides the infrastructure that allows trusted consumer-facing companies to integrate healthcare services directly into their apps and websites. Its model is designed to ease pressure on the UK’s National Health Service, which continues to face long waiting times for routine care. In 2024, more than 20 million people in the UK waited longer than a month to secure a GP appointment.
Founded in 2018, Evaro was set up by emergency physician Dr Thuria Wenbar and pharmacist-researcher Dr Oskar Wenbar. The founders have said the idea grew out of their first-hand experience of seeing patients struggle with delays in receiving treatment for common conditions. Their aim was to provide convenient and compliant healthcare services in digital spaces that patients already use.
At the centre of Evaro’s offering is its “healthcare-as-a-service” model. Through an API-first platform, the company allows brands such as Clue and Lovehoney Group to embed a full clinical stack into their consumer applications. According to the company, the platform can be deployed in as little as two weeks.
The services supported by Evaro range from asynchronous consultations and remote diagnostics to automated dispensing and aftercare. The platform currently covers more than 80 medical conditions and has been used by over two million patients to date.
Regulatory compliance is a key part of Evaro’s proposition. Over the past seven years, the company has secured licences from the NHS, the Care Quality Commission (CQC) and the General Pharmaceutical Council (GPhC). Holding approvals from all three bodies allows consumer brands to legally and safely provide prescription services, a capability that distinguishes Evaro from many other digital health providers.
As part of the investment, AlbionVC partner Christoph Ruedig will join Evaro’s board. AlbionVC has compared the company’s growth potential to the rise of embedded finance, positioning Evaro as a driver of what it sees as an emerging embedded health category. The firm believes the model can unlock significant unmet demand for healthcare while reducing strain on public services such as the NHS.
The new funding will be used to support Evaro’s next phase of growth. The company plans to expand beyond its current focus on women’s and men’s health into areas including longevity and advanced diagnostics. It also intends to build new partnerships with consumer brands, healthcare providers and employer benefits programmes.
The Series A round marks a major milestone for Evaro as it looks to scale its platform across the UK and beyond. By enabling well-known brands to act as new entry points to healthcare, the company is positioning itself as a key player in reshaping how patients access medical services in a digital-first environment.
